Futura Medical PLC (FUM:AIM) delivered its 2025 interim results investor update, highlighting a challenging trading period but reaffirming long-term growth opportunities. Interim CEO Alex Duggan outlined a strategic review following slower-than-expected repeat sales of Eroxon across key markets including the US, EU, Middle East, and Latin America. H1 revenues reached just over £1 million, with gross profit of £0.7 million offset by a £0.49 million inventory provision and a £3.6 million impairment, resulting in a £6.6 million loss after tax. Cash at period end stood at £3.69 million, providing runway into January 2026, with management actively exploring financing and commercial options to extend liquidity. Despite revenue expectations being downgraded to £1.3–1.4 million for FY25, the board remains confident in the value of its pipeline. Development projects include Eroxon Intense, targeting stronger consumer efficacy and expected to receive EU and US regulatory approval by year-end 2025, and WSD 4000, a novel female sexual health treatment with significant unmet demand and FDA support, targeting launch by 2028. The company continues to strengthen patent protection across major markets and is engaged with partners on potential new launches in Brazil, Taiwan, and China. While near-term performance remains under pressure, Futura is focused on cost reductions, refining product positioning, and enhancing consumer education to drive repeat sales and improve margins. Management emphasized commitment to protecting shareholder value and progressing innovation in consumer healthcare.

Serica Energy PLC (SQZ:AIM) has announced the acquisition of Prax Upstream in a value-accretive transaction designed to enhance reserves, diversify production, and strengthen cash flow generation. The deal, which includes 100% of the Lancaster field, stakes in the Greater Lagan Area (GLA), Catcher, and the Golden Eagle Area Development, is set to add approximately 11 million 2P barrels at an attractive acquisition price of just $2.3 per boe—well below the North Sea average. Supported by strong tax synergies, including over $2 billion in tax losses, the acquisition is expected to deliver an immediate boost to free cash flow, with Serica forecasting an incremental $50 million in 2026. Strategically, the move positions Serica for further growth in the UK North Sea, particularly in the West of Shetland Basin, where significant upside potential exists through infill drilling, undeveloped discoveries, and third-party throughput opportunities via the Shetland Gas Plant. Management emphasized that the transaction not only strengthens the balance sheet and cash generation but also supports future M&A, while maintaining low decommissioning liabilities relative to peers. CEO Chris Cox and CFO Martin Copeland highlighted that the acquisition is aligned with Serica’s long-term growth strategy of securing mid-to-late-life producing assets where the company can unlock additional value. With integration of experienced Prax personnel, diversification of production hubs, and enhanced shareholder returns through stronger cash flows, Serica Energy reinforced its commitment to disciplined capital allocation, future M&A opportunities, and delivering sustainable value for investors.

Poolbeg Pharma plc (POLB:AIM) delivered an investor update highlighting strong progress across its clinical pipeline and financial position. The clinical-stage biopharmaceutical company is advancing two high-value programmes: POLB 001, a Phase 2a trial targeting cytokine release syndrome (CRS) associated with cancer immunotherapies, and an oral GLP-1 obesity treatment. With FDA orphan drug designation secured for POLB 001 and drug supply provided at no cost, the company is well-positioned to deliver proof-of-concept data, with interim results expected in summer 2023. Management emphasised the significant unmet medical need in oncology, where CRS affects up to 70% of patients, and highlighted POLB 001’s potential to become the first preventative oral therapy, unlocking opportunities in a market estimated at $10bn. The oral GLP-1 programme, meanwhile, aims to address a multi-billion-dollar obesity market, with topline data expected in the first half of next year. Poolbeg maintains a cash runway to 2027, ensuring funding for near-term value inflection points. The company’s growth strategy centres on partnering with major pharma, leveraging its proven track record in clinical development, intellectual property protection, and deal-making. With a strong order book of clinical milestones, a focus on high-margin opportunities, and the potential to broaden access to cancer immunotherapies, Poolbeg presents a compelling investment case.

NAHL Group PLC (AIM: NAH) reported a strong set of interim results for the six months ended 30 June 2025, highlighting solid operational progress, robust cash generation, and continued balance sheet improvement. Group revenue was stable at £19.2m, while profit before tax surged 289% to £1.9m, driven by an 89% increase in operating profit from Consumer Legal Services and resilient performance in Critical Care. Basic earnings per share rose over 300% to 3p, supported by free cash flow of £1.5m and a reduction in net debt to a 10-year low of £5.6m. In Consumer Legal Services, National Accident Law settled 1,648 claims, delivering £5.3m in cash—up 33% year-on-year—with average settlement values 57% higher. Lead generation stabilized, acquisition costs fell below historical levels, and personal injury operating profit more than doubled. In Critical Care, Bush & Co. achieved 2% revenue growth, maintained strong margins of 31.5%, and expanded its expert witness network, issuing 719 reports (+30% YoY) with outstanding client satisfaction scores. New initiatives, including Bush & Co. Kids and Care Solutions, are expected to strengthen long-term recurring revenues. Management reiterated confidence in meeting full-year market expectations, underpinned by a growing order book, disciplined cost control, and strategic focus on higher-value claims and specialist care markets. With net debt at historic lows and strong cash conversion, NAHL is well positioned to invest in growth opportunities across both divisions. Investors were reassured by management’s commitment to sustaining earnings momentum into FY2026, supported by operational efficiencies, AI-driven process improvements, and potential strategic investments or acquisitions to unlock further shareholder value.

Pantheon Infrastructure PLC (PINT:LSE) delivered a strong investor update highlighting resilient performance and strategic portfolio growth. The company reported an 18% year-on-year increase in EBITDA to £78m, alongside 17% revenue growth and a NAV uplift of 4.6% in the first half, supported by significant valuation gains from Calpine. PINT increased its interim dividend by 3.5% to 2.173p, with full dividend coverage expected in 2025 driven by $35m of Calpine proceeds. The portfolio now spans 13 diversified infrastructure assets across digital, utilities, and renewables, with a disciplined focus on contracted revenues, inflation protection, and downside resilience. PINT also announced a new commitment to Intersect Power, a large-scale U.S. renewable energy platform supporting AI-driven data centre demand with solar, battery, and modular gas solutions. Admission to the FTSE 250 in June marks a key milestone, while a narrowing share price discount reflects investor confidence and strong sector positioning. With nearly £25bn of AUM across Pantheon’s wider platform, PINT continues to leverage scale, sponsor relationships, and disciplined capital allocation to target 8–10% NAV total returns. Management reaffirmed its strategy of holding assets over the medium term, recycling capital into high-quality growth opportunities, and maintaining a conservative approach to leverage. The outlook remains positive, underpinned by robust cash flow visibility, diversification, and exposure to long-term megatrends in digital infrastructure, energy transition, and regulated utilities.

Gresham House Energy Storage Fund plc (GRID:LSE) delivered its interim results with a clear focus on growth, financial resilience, and long-term value creation. Despite a modest 1.5% decline in NAV per share to 107.7p, driven by lower third-party revenue forecasts, the company reported a near doubling of EBITDA on the back of stronger revenue rates and increased capacity. GRID has now surpassed 1GW of operational projects and successfully refinanced and upsized its debt facility to £220m at improved terms, supporting its ambitious three-year growth strategy. This plan includes augmentations, the build-out of a 694MW pipeline, and contracted floor revenues across 100% of new assets, de-risking cash flows while reducing the cost of capital. Management reinstated a modest dividend to balance shareholder returns with reinvestment, with the potential for significantly higher dividends and share buybacks from 2027 as construction spend tapers and cash flow expands. The portfolio is expected to grow to 1.8GW with an average duration of 1.6 hours, positioning GRID as the UK’s market leader in battery energy storage. Regulatory reforms, including Ofgem’s GC0166 and the roll-out of the Open Balancing Platform, are anticipated to improve battery utilisation and revenue visibility. Looking ahead, GRID’s strategy leverages contracted revenues, low battery costs, and alternative revenue streams to capture upside, while maintaining debt-to-NAV within policy limits. With strong government support for the energy transition, a robust order book, and scale advantages, Gresham House Energy Storage Fund is well placed to deliver sustainable growth, resilient cash flows, and enhanced shareholder value.

Surgical Innovations Group plc (SUN:AIM) reported its Interim Results with management highlighting a strong operational and strategic platform for future growth. The company achieved full MDR certification across all product groups, a significant milestone that frees resources for R&D, compliance, and efficiency initiatives while strengthening its competitive position ahead of the 2028 regulatory deadline. Revenue for H1 2025 was broadly flat year-on-year, with stable UK sales, strong momentum in Europe and Japan, but continued challenges in the US due to tariffs. Gross margin improved from FY2024 levels, supported by restructuring and cost-saving measures, though price pressures remain. Adjusted EBITDA, operating profit, and EPS showed marked improvement as benefits from the 2024 cost-reduction program flowed through. Strategic highlights included the introduction of new third-party products, expansion of the SI brand, and an OEM pipeline showing early signs of growth beyond AMS partnerships. Upcoming launches such as the Logicube Lux and enhancements to the Yellow Port Elite range are expected to support revenue growth and margin improvement from 2026, alongside cost-down initiatives on high-volume consumables. Sustainability continues to differentiate Surgical Innovations in the UK, Europe, and Japan, with its environmental and financial calculator demonstrating significant reductions in CO2, plastic waste, and costs for healthcare providers. New board appointments, including Roy Davies as Chairman, bring deep sector expertise to drive shareholder value. With reduced borrowings, improved working capital management, and a stronger cost base, the company is positioned to deliver sustainable long-term growth, leveraging its innovation pipeline, expanding international footprint, and sustainability-led strategy.

CT Automotive Group plc (AIM: CTA) delivered its H1 2025 investor update, highlighting resilient performance and strong margin improvement despite industry-wide tariff volatility and program timing shifts. Revenue came in at $54.1m, with gross profit margins rising 290bps to 30.5% driven by AI-led automation, digitization, and footprint optimization. Adjusted EBITDA increased to $8.4m, while adjusted profit before tax reached $4.2m. Net debt, temporarily elevated at $12.1m, normalized to $7.4m in July and is expected to close FY25 at $9–10m. Operational cash generation remains robust, supported by cost discipline and efficiency gains. Strategic investments in Mexico, including $3.4m of capex for additional molding capacity and an automated paint line, underpin future growth and position the company to benefit from USMCA-driven supply chain shifts. Eight new program wins worth $37m annually, including relocations from competitors, enhance CT Automotive’s long-term order book and pipeline visibility. The company’s request-for-quotation book is at record highs, reflecting demand from both established OEMs and next-generation EV manufacturers. With operations spanning China, Turkey, and Mexico, CT Automotive is leveraging vertical integration, flexible production, and AI innovation to drive competitive landed costs, margin enhancement, and sustainable growth. Management reaffirmed confidence in meeting FY25 profit targets and expects volumes to ramp meaningfully in 2026, supported by a diversified customer base across volume, premium, and EV platforms. Investors were also updated on governance, sustainability, and cybersecurity initiatives, alongside the company’s longer-term strategy to maximize shareholder value. Overall, CT Automotive remains well-positioned to capture market share in a rapidly evolving global automotive sector.

Aurrigo International PLC (AURR:AIM) delivered its interim results for the six months ended 30 June 2025, highlighting strong commercial momentum in autonomous transport solutions for airports and logistics. The company, a leader in autonomous electric airside vehicles, showcased significant progress with its Auto-Dolly, Auto-Cargo, and Auto-Shuttle platforms, supported by proprietary software including Auto-SIM, Auto-Stack, and Auto-Connect. Strategic partnerships, notably with Swissport and UPS, are positioning Aurrigo for large-scale global deployments, with trials underway across the UK, North America, Canada, and Asia. Despite softer automotive revenues impacted by tariffs, group gross profit improved due to a higher-margin mix from autonomous operations. EBITDA losses widened as investment scaled to support growth, underpinned by a £14.2m fundraise and new strategic investors, strengthening the balance sheet and funding expansion of manufacturing capacity in the UK, US, and Asia. Management reiterated that the addressable market for autonomous aviation solutions could reach $20bn by 2032, with more than 700 airports globally offering a clear business case for adoption. Aurrigo expects 2026 to be a transformational year as small-scale deployments transition to full fleet rollouts, with SaaS-style revenue models enhancing long-term earnings visibility. With strong market tailwinds, government support, and proprietary technology differentiating it from competitors, Aurrigo believes it is well positioned to scale internationally, improve margins, and deliver sustainable shareholder value.

Huddled Group PLC (HUD:AIM) delivered a strong Half Year 2025 investor update, reporting 81% revenue growth to £9.5m and a swing to positive gross profit of £190k, compared with a loss last year. Discount Dragon improved basket margins by 20% and achieved operational profitability in August and September, underpinned by a sharper product mix and disciplined margin management. Nutri Circle was the standout performer, with orders up 768% and revenue up 621% year-on-year, exceeding £2.5m in H1 and set to deliver more revenue in Q3 than its entire FY2024. Boop, though only a year old, generated £1.6m in H1 revenue with rapid order growth and a growing customer base. Across the group, adjusted EBITDA loss narrowed to £1.5m, supported by a £1.5m institutional investment that strengthened the balance sheet and provides runway to full profitability. Management highlighted the strategic move to THG Ingenuity’s automated fulfilment platform, expected to unlock next-day delivery, lower costs, and improve customer retention. With enhanced supply partnerships, broadened product ranges, and rising repeat order volumes, Huddled is positioned for continued margin expansion, revenue growth, and progression toward group profitability. The company reinforced its dual focus on commercial performance and ESG impact, preventing more than 4m surplus items from going to waste in H1 alone. Investors were told to expect further growth momentum into Q4, underpinned by stronger customer engagement, operational efficiencies, and a robust growth strategy across Discount Dragon, Nutri Circle, and Boop.